Drug Approval | November 20, 2023
Lupin receives approval from US FDA for Ganirelix Acetate Injection
The product will be manufactured at Lupin’s Nagpur facility in India
The product will be manufactured at Lupin’s Nagpur facility in India
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Phase 3 data expected in the second half of 2024
Yesafili, received marketing authorization approval from the European Commission for the European Union
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Subscribe To Our Newsletter & Stay Updated
